Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RPRX Stock Forecast 2026-2027
$55.67
Current Price
$32.06B
Market Cap
Buy 8
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to RPRX Price Targets
+18.6%
To High Target of $66.00
+7.8%
To Median Target of $60.00
-17.4%
To Low Target of $46.00
RPRX Price Momentum
-4.6%
1 Week Change
+2.6%
1 Month Change
+52.5%
1 Year Change
+44.1%
Year-to-Date Change
-5.4%
From 52W High of $58.84
+63.3%
From 52W Low of $34.08
📊 TOP ANALYST CALLS
Did RPRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Royalty Pharma is one of their latest high-conviction picks.
Latest RPRX Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, RPRX has a bullish consensus with a median price target of $60.00 (ranging from $46.00 to $66.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $55.67, the median forecast implies a 7.8% upside. This outlook is supported by 8 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Geoff Meacham at Citigroup, projecting a 18.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RPRX Analyst Ratings
8
Buy
2
Hold
0
Sell
RPRX Price Target Range
Low
$46.00
Average
$60.00
High
$66.00
Current: $55.67
Latest RPRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RPRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 13, 2026 | TD Cowen | Steve Scala | Buy | Maintains | $65.00 |
| May 7, 2026 | Citigroup | Geoff Meacham | Buy | Maintains | $66.00 |
| May 7, 2026 | JP Morgan | Chris Schott | Overweight | Maintains | $58.00 |
| Apr 21, 2026 | UBS | Buy | Maintains | $N/A | |
| Apr 10, 2026 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Jan 30, 2026 | UBS | Buy | Upgrade | $N/A | |
| Jan 27, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Dec 11, 2025 | TD Cowen | Buy | Maintains | $N/A | |
| Oct 10, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Sep 30, 2025 | Goldman Sachs | Buy | Initiates | $N/A | |
| Jul 22, 2025 | Citigroup | Buy | Maintains | $N/A | |
| Jul 10, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Oct 25, 2024 | Citigroup | Buy | Maintains | $N/A | |
| Aug 14, 2024 | Goldman Sachs | Buy | Maintains | $N/A | |
| Jul 11, 2024 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Jun 3, 2024 | UBS | Neutral | Downgrade | $N/A | |
| Apr 12, 2024 | B of A Securities | Buy | Maintains | $N/A | |
| Feb 20, 2024 | JP Morgan | Overweight | Maintains | $N/A | |
| Feb 20, 2024 | Goldman Sachs | Buy | Maintains | $N/A | |
| Nov 9, 2023 | Morgan Stanley | Overweight | Maintains | $N/A |
Royalty Pharma plc (RPRX) Competitors
The following stocks are similar to Royalty Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
RPRX
Royalty Pharma
mkt cap
32.49B
Royalty Pharma plc (RPRX) Financial Data
Royalty Pharma plc has a market capitalization of $32.06B with a P/E ratio of 29.7x. The company generates $2.44B in trailing twelve-month revenue with a 33.9% profit margin.
Revenue growth is +11.0% quarter-over-quarter, while maintaining an operating margin of +100.3% and return on equity of +13.8%.
Valuation Metrics
Market Cap
$32.06B
Enterprise Value
$36.43B
P/E Ratio
29.7x
PEG Ratio
1.6x
Price/Sales
13.3x
Growth & Margins
Revenue Growth (YoY)
+11.0%
Gross Margin
N/A
Operating Margin
+100.3%
Net Margin
+33.9%
EPS Growth
+23.1%
Financial Health
Cash/Price Ratio
+2.5%
Current Ratio
2.7x
Debt/Equity
90.3x
ROE
+13.8%
ROA
+5.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Royalty Pharma plc (RPRX) Business Model
About Royalty Pharma plc
What They Do
Acquires biopharmaceutical royalties for funding innovation.
Business Model
The company generates revenue by acquiring royalties that entitle it to payments based on the net sales of approved therapies and development-stage products. It partners with a diverse range of innovators, including academic institutions, research hospitals, and biotechnology firms, providing non-dilutive funding solutions to support clinical trials and product launches.
Additional Information
With a portfolio of royalties on over 35 commercial products addressing various medical conditions, Royalty Pharma holds a dominant market position in biopharma royalty transactions. Founded in 1996 and based in New York, it plays a crucial role in accelerating bio-innovation in the life sciences sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
100
CEO
Mr. Pablo Legorreta
Country
United States
IPO Year
2020
Website
www.royaltypharma.comRoyalty Pharma plc (RPRX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Why Royalty Pharma (RPRX) Could Beat Earnings Estimates Again
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Jul 10, 2026
By Zacks Equity Research
Tale of the Tape
Are You Looking for a Top Momentum Pick? Why Royalty Pharma (RPRX) is a Great Choice
Does Royalty Pharma (RPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Jul 10, 2026
By Zacks Equity Research
Tale of the Tape
RPRX or ACAD: Which Is the Better Value Stock Right Now?
RPRX vs. ACAD: Which Stock Is the Better Value Option?
Jul 09, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Zacks Earnings ESP tool aids investors in identifying stocks likely to surpass quarterly earnings estimates, simplifying the analysis process.
Why It Matters
The Zacks Earnings ESP tool enhances stock selection by highlighting companies likely to surpass earnings forecasts, potentially leading to profitable investment opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Royalty Pharma (RPRX) has a strong history of earnings surprises and is well-positioned for a potential earnings beat in its upcoming quarterly report.
Why It Matters
Royalty Pharma's strong earnings surprise history and favorable conditions suggest potential upward earnings revisions, which can boost investor confidence and stock price.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Royalty Pharma (RPRX) is being evaluated as a potential top stock pick for momentum investors. Further analysis may provide insights into its performance and suitability.
Why It Matters
Momentum investors seek stocks with upward price trends. Royalty Pharma's potential as a top pick suggests it may experience significant price appreciation, attracting attention and capital.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Royalty Pharma (RPRX) reaches a 52-week high. Investors are encouraged to examine the company's fundamentals for potential future gains.
Why It Matters
Royalty Pharma's 52-week high signals strong momentum, but analyzing its fundamentals will reveal potential for sustained growth or risk of a downturn.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors in Medical - Biomedical and Genetics stocks are considering Royalty Pharma (RPRX) and Acadia Pharmaceuticals (ACAD) as potential undervalued options.
Why It Matters
The comparison of Royalty Pharma and Acadia Pharmaceuticals highlights potential investment opportunities in undervalued biomedical stocks, influencing investment strategies and portfolio decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Healthcare is considered a defensive sector with stable demand, offering differentiated investment opportunities amid trends in AI and space.
Why It Matters
Healthcare's defensive nature amid economic fluctuations offers stability, making it an attractive alternative to the volatile AI and space sectors for investors seeking resilience.
Source: ETF Trends
Market Sentiment:
Positive
Frequently Asked Questions About RPRX Stock
What is Royalty Pharma plc's (RPRX) stock forecast for 2027?
Based on our analysis of 4 Wall Street analysts, Royalty Pharma plc (RPRX) has a median price target of $60.00. The highest price target is $66.00 and the lowest is $46.00.
Is RPRX stock a good investment in 2027?
According to current analyst ratings, RPRX has 8 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $55.67. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RPRX stock?
Wall Street analysts predict RPRX stock could reach $60.00 in the next 12 months. This represents a 7.8% increase from the current price of $55.67. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Royalty Pharma plc's business model?
The company generates revenue by acquiring royalties that entitle it to payments based on the net sales of approved therapies and development-stage products. It partners with a diverse range of innovators, including academic institutions, research hospitals, and biotechnology firms, providing non-dilutive funding solutions to support clinical trials and product launches.
What is the highest forecasted price for RPRX Royalty Pharma plc?
The highest price target for RPRX is $66.00 from Geoff Meacham at Citigroup, which represents a 18.6% increase from the current price of $55.67.
What is the lowest forecasted price for RPRX Royalty Pharma plc?
The lowest price target for RPRX is $46.00 from at , which represents a -17.4% decrease from the current price of $55.67.
What is the overall RPRX consensus from analysts for Royalty Pharma plc?
The overall analyst consensus for RPRX is bullish. Out of 4 Wall Street analysts, 8 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $60.00.
How accurate are RPRX stock price projections?
Stock price projections, including those for Royalty Pharma plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 15, 2026 1:31 PM UTC